Literature DB >> 8344428

Osteoblast-like cells have a variable mixed population of purino/nucleotide receptors.

H Yu1, J Ferrier.   

Abstract

Osteoblast-like UMR 106.06 cells respond to extracellular application of nucleotides with a fast intracellular calcium pulse (latency of about 20 s, half-width of about 10 s), as measured with fluo-3 on a confocal laser scanning system. Cross-inhibition experiments at 50 microM show that, on a cell population basis, adenosine triphosphate (ATP) strongly inhibits the effect of uridine triphosphate (UTP) or 2-methylthio-ATP (2-MeSATP) applied within 2 min after the end of the ATP-induced pulse, while prior application of UTP or 2-MeSATP only weakly inhibits the ATP effect, and UTP and 2-MeSATP weakly inhibit each other. Furthermore, there are clear differences in cross-inhibition between individual cells. Our measurements provide strong evidence that these cells have at least two types of purino/nucleotide receptors, probably P2y and P2u, with a proportion that varies between individual cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8344428     DOI: 10.1016/0014-5793(93)80994-6

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  4 in total

Review 1.  Purinergic signalling in the musculoskeletal system.

Authors:  Geoffrey Burnstock; Timothy R Arnett; Isabel R Orriss
Journal:  Purinergic Signal       Date:  2013-08-14       Impact factor: 3.765

2.  ATP and adenosine act as a mitogen for osteoblast-like cells (MC3T3-E1).

Authors:  S Shimegi
Journal:  Calcif Tissue Int       Date:  1996-02       Impact factor: 4.333

3.  Evidence of ectokinase-mediated phosphorylation of osteopontin and bone sialoprotein by osteoblasts during bone formation in vitro.

Authors:  X Zhu; C Luo; J M Ferrier; J Sodek
Journal:  Biochem J       Date:  1997-05-01       Impact factor: 3.857

4.  P2 receptors in macrophage fusion and osteoclast formation.

Authors:  Thomas H Steinberg; Jeffrey F Hiken
Journal:  Purinergic Signal       Date:  2007-02-06       Impact factor: 3.765

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.